Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Raises HANSOH PHARMA (03692.HK) TP to $33.3, Reiterates Rating at Buy
Recommend 6 Positive 6 Negative 2 |
||||
|
||||
|
UBS issued a research report believing that HANSOH PHARMA (03692.HK)'s share price is still undervalued, even after a 53% rally YTD. UBS raised its 2025-2027 EPS forecasts for HANSOH PHARMA by 16.2%/ 17.7%/ 21.3% each, and its revenue forecasts by 6-12%. The broker expected Aumolertinib and business development (BD) to be the main drivers, and predicted Aumolertinib's sales to reach RMB6 billion in 2025 and peak at RMB8 billion in 2029. Therefore, UBS raised its target price from $24 to $33.3, with rating reiterated at Buy. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
